The gross proceeds to the Company from the offering are expected to be approximately $2.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company ...

This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early ...

BLEG's R&D collaborations with McMaster University and Stanford University will continue to advance formulation, testing, and translational development of the inhaled naloxone program and other ...

The 2025 Life Science Innovation Forum (LSIF) is a two-day international event hosted in Riyadh, Saudi Arabia. This prestigious forum serves as a platform to accelerate the conversion of cutting-edge ...

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as ...

CHATHAM, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a ...

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective ...

Figure 1. BreathLogix Alcohol device available with contactless and straw modes for rapid workplace pre-access alcohol screening ...

(Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish ...

MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S.

Anavex will continue to evaluate the Phase IIb/III early Alzheimer’s disease and ATTENTION-AD trial data, which will be published and presented at international AD conferences.

Current diagnostic tools, like dual-energy X-ray absorptiometry (DXA), primarily measure bone mineral density (BMD), which explains only about 70% of bone strength variability. OsteoProbe® addresses ...